Species-Wide Genetic Atlas of Antimicrobial Resistance in *Clostridioides difficile*

Korakrit Imwattana¹ , César Rodríguez² , Thomas V Riley1,3,4,5 and Daniel R Knight 1,3

¹ School of Biomedical Sciences, The University of Western Australia, Western Australia ² Facultad de Microbiología & Centro de Investigación en Enfermedades Tropicales (CIET), Universidad de Costa Rica, Costa Rica ³ School of Veterinary and Life Sciences, Murdoch University, Western Australia ⁴ School of Medical and Health Sciences, Edith Cowan University, Western Australia ⁵ Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Western Australia

- 1. All publicly available read files were downloaded.
- 2. All non-redundant illumina read files were screen for quality and contamination using kraken2⁴ .
- 3. Read files of epidemic strains (sequence types (STs) 1, 2, 11 and 37) were screened for clonality (nucleotide identity > 99.98%) using SRST2⁵ and Sketch⁶, respectively.
- 4. All remaining read files were interrogated against several AMR databases.#

Results

1. Population structure of *C. difficile*

Background and Objectives

Antimicrobial resistance (AMR) plays an important role in the spread and pathogenesis of *Clostridioides difficile* infection (CDI). An association between AMR and CDI outbreaks has been identified^{1,2,3}, however, such studies have been limited to a few strains in limited geographical regions.

References

1. Dingle KE, *et al.* (2019). **MBio**;10(2):e02790-18. 2. He M, *et al.* (2013). **Nat Gen**; 45(1):109-13. 3. Imwattana K, *et al.* (2020). **Expert Rev Anti Infect Ther**;1:17-25. 4. Wood DE, *et al.* (2019). **Genome Biol**;20(1):257. 5. Inouye M, *et al.* (2014). **Genome Med**;6(11):90. 6. BBtools package [available at https://sourceforge.net/projects/bbmap/] 7. PubMLST database [available at https://pubmlst.org/cdifficile/] 8. Gubta SK, *et al.* (2014). **Antimicrob Agents Chemother**;58(1):212-20. 9. Zankari E, *et al.* (2012). **J Antimicrob Chemother**; 67(11):2640-4.

Conclusion

There was a higher prevalence of AMR among epidemic *C. difficile* lineages. Despite its intrinsic resistance, some *C. difficile* strains carried aminoglycoside resistance genes, suggesting its role as a reservoir of AMR genes.

This study aimed to investigate the prevalence of AMR genotypes in the global population of *C. difficile***.**

Re-Defining *Clostridioides difficile* **Using Global Phylogenomic Analyses**

Korakrit Imwattana¹ , César Rodríguez 2 , Thomas V Riley 1,3,4,5 and Daniel R Knight 1,3

- ¹ School of Biomedical Sciences, The University of Western Australia, Western Australia
- ² Facultad de Microbiología & Centro de Investigación en Enfermedades Tropicales (CIET), Universidad de Costa Rica, Costa Rica
- Medical, Molecular and Forensic Sciences, Murdoch University, Western Australia
- ⁴ School of Medical and Health Sciences, Edith Cowan University, Western Australia
- ⁵ Department of Microbiology, PathWest Laboratory Medicine, Western Australia

Background and Objectives

- C-I Fructosamine utilisation
- C-II EDTA resistance
- C-III Ethanolamine catabolism
	- Fructosamine utilisation
	- Polyamine biosynthesis

Clostridioides difficile **species problem:** A diverse population classified into a single species based on 16s rRNA **Study Objective:** Use ANI to re-evaluate the species definition of *C. difficile*

> **Large toxin genes** | Regulatory genes **Binary toxin genes Excisionase genes**

2. Bayesian evolutionary analysis reveals cryptic clades are ancient species

Total gene repertoire 17,470 genes

Core gene 2,232 genes (12.8%)

Potential specific phenotypes

3. Pan-genome analysis identifies clade specific genes and traits

4. Cryptic clades harbor novel and highly divergent toxin gene architecture identifies

- 1. Konstantinidis KT, *et al.* (2006) **Philos Trans R Soc Lond B Biol Sci**;361:1929-1940.
- 2. Wayne LG, *et al.* (1987) **Int J Syst Evol Microbiol**;37:463-464.
- 3. Stackebrandt E, *et al.* (1994) **Int J Syst Evol Microbiol**;44:846-849
- 4. Jain C, *et al.* (2018) **Nat Commun**;9:5114.
- 5. Pritchard L, *et al.* (2016) **Anal Methods**;8:12-24.
- 6. Didelot X, *et al.* (2018) **Nucleic Acids Res**;46:e134-e134.
- 7. Drummond AJ, *et al.* (2007) **BMC Evol Biol**;7:214.
- 8. Tonkin-Hill G, *et al.* (2020) **Genome Biol**;21:180.
- 9. Brynildsrud O, *et al.* (2016) **Genome Biol**;17:238.

Conclusions References

There was a clear species boundary separating *C. difficile* from the 3 novel genomospecies. Several potential phenotypic differences were identified. Difference in toxin gene architecture and its divergence may complicate the diagnosis of *C. difficile* infection.

